Iron chelator delivery system

Details Iron chelator delivery system Iron chelator delivery system

2005-11-01

2005-11-01

Saunders, David (Department: 1644)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C424S152100, C424S172100, C424S178100, C424S450000, C514S616000

Reexamination Certificate

active

06960560

ABSTRACT:
An iron chelator delivery system is disclosed. The system comprises iron chelator and a lipid carrier, e.g., a liposome. Methods for preparing and administering the iron chelator delivery system are also provided.

REFERENCES:
patent: 4920016 (1990-04-01), Allen et al.
patent: 5534241 (1996-07-01), Torchilin et al.
patent: 5585112 (1996-12-01), Unger et al.
patent: 5854007 (1998-12-01), Ritter et al.
patent: 0068314 (1982-06-01), None
patent: WO 92/01068 (1992-01-01), None
Hopkins, S.J., et al., “Liposome-Entrapped Desferrioxamine.”Drugs of the Future, vol. 4, No. 7, pp.: 500-506 (1979).
Klibanov, Alexander L. et al., “Trageting of macromolecular carriers and liposomes by antibodies to myosin heavy chain.”American Journal of Physiology,vol. 261, No. 4, Suppl., pp.: 60-65 (1991).
Lau, E.H. et al., “Improvement of Iron removal from reticuloendothelial system by liposome encapsulation of N,N′-bis[2-hydroxy-benzyl]-ethylenediamine-N.N′-diacetic acid (HBED).”Journal of Laboratory and Clinical Medicine,vol. 101, No. 5, pp.: 806-816 (1983).
Lau, E.H. et al., “Liposome-encapsulated Desferrioxamine in Experimental Iron Overload.”British Journal of Haematology,vol. 47, pp.: 505-518 (1981).
Postma, N.S. et al., “Absorption and biodistribution of111indium-labelled desferrioxamine (111In-DFO) after subcutaneous injection of111In-DFO liposomes.”Journal of Controlled Release, vol. 58, pp.: 51-60 (1999).
Rahman, Yueh-Erh et al., “Liposomes as Delivery System for Iron Chelators.”Dev Iron Chelators Clin. Use,Proc. Symp., 2nd, pp.: 211-225 (1981).
Rahman, Yueh-Erh et al., “Application of Liposomes to Metal Chelation Therapy.”Liposomes Immunobiol.,Proc. Natl. Symp., pp.: 285-299 (1980).
Young, S.P. et al., “Liposome Entrapped Desferrioxamine and Iron Transporting Ionophores: a New Approach to Iron Chelation Therapy.”British Journal of Heamatology,vol. 41, pp.: 357-363 (1979).
Torchillin et al., “Preservation of antimyosin antibody after covalent coupling to liposomes,” Biochem. Biophys. Res. Commun. 89(4), 1114-1119, 1979.
Dufresne et al., “Targeting lymph nodes with liposomes bearing anti-HLA-DR Fab' fragments,” Biochim. Biophys. Acta, 1421(2), 284-294, 1999.
Maruyama et al., “Lipid composition is important for highly efficient target binding and retention of immunoliposomes,” Proc. Nat'l. Acad. Sci., USA, 87:5744-5748, 1990.
Maruyama et al., “Possibility of active targeting to tumor tissues with liposomes,” Adv. Drug. Deliv. Rev., 40 (1-2), 89-102, 1999.
Vingerhoeds et al., “Immunoliposomes in Vivo,” Immunomethods, 4(3), 259-272, 1994.
Leserman et al., “Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A,” Nature, 288:602-604, 1980.

Affiliated with

Also associated with

Rating

Iron chelator delivery system does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Iron chelator delivery system, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Iron chelator delivery system will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3465754